{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:02:55Z","timestamp":1793023375518,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006676","name":"Lilly Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006676","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study evaluates type 2 diabetes mellitus (T2DM) prevalence in Germany, focusing on patients at risk for, or with already established, cardiovascular disease (CVD), as well as their antidiabetic and cardiovascular treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Using anonymized claims data from the WIG2 database, we calculated 2018 T2DM prevalence, extrapolating rates to the German statutory health insurance population. In the study period, 3\u2009376\u2009228 patients were eligible in the database. Forming antidiabetic medication groups, we evaluated treatment regimens of patients at risk for, or with already established CVD, based on the REWIND study criteria. We also evaluated their CVD medication prescriptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Statutory health insurance extrapolated T2DM prevalence was estimated at 11.9%, with higher prevalence rates in older patients. When only patients with prescriptions of antidiabetic drugs were included, prevalence was 7.6%. At least 94% of patients with T2DM medication had at least one risk factor (without considering age) according to REWIND criteria, while 67%\u201080% had at least two risk factors depending on treatment received. Patients taking insulin combined with oral therapy comprised the largest proportion of patients with at least two REWIND risk factors. Approximately 85% of all patients with T2DM in the population were treated with antihypertensive medication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>T2DM is widespread and affects older patients particularly. Most patients with T2DM had at least one CV risk factor, and about half already had established CVD. Early prevention of CVD, which disproportionately affects patients with T2DM, is necessary. Furthermore, the treatment of older patients with T2DM with insulin is still common and needs further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.14924","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T02:37:19Z","timestamp":1669948639000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Age\u2010dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data"],"prefix":"10.1111","volume":"25","author":[{"given":"Thorsten","family":"Otto","sequence":"first","affiliation":[{"name":"Lilly Deutschland GmbH  Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-583X","authenticated-orcid":false,"given":"Joanna","family":"Diesing","sequence":"additional","affiliation":[{"name":"Scientific Institute for Health Economics and Health System Research (WIG2 GmbH)  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Borchert","sequence":"additional","affiliation":[{"name":"Scientific Institute for Health Economics and Health System Research (WIG2 GmbH)  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Heitmann","sequence":"additional","affiliation":[{"name":"Lilly Deutschland GmbH  Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-4316","authenticated-orcid":false,"given":"Nanette","family":"C. Schloot","sequence":"additional","affiliation":[{"name":"Lilly Deutschland GmbH  Bad Homburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremie","family":"Lebrec","sequence":"additional","affiliation":[{"name":"HaaPACS GmbH  Schriesheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-6442","authenticated-orcid":false,"given":"Dirk","family":"M\u00fcller\u2010Wieland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I University Hospital Aachen, RWTH Aachen University  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8542-693X","authenticated-orcid":false,"given":"Dennis","family":"Haeckl","sequence":"additional","affiliation":[{"name":"Scientific Institute for Health Economics and Health System Research (WIG2 GmbH)  Leipzig Germany"},{"name":"Faculty of Economics and Management Leipzig University  Leipzig Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas.10th Edition;2021. Accessed March 14 2022.https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf."},{"key":"e_1_2_10_3_1","unstructured":"GoffrierB SchulzMandy B\u00e4tzing\u2010FeigenbaumJ.Administrative Pr\u00e4valenzen Und Inzidenzen Des Diabetes Mellitus Von 2009 Bis 2015;2017."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.720847"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1360"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807233390404"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037885"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0583-x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010018\u20100728\u20106"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-05039-w"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13028"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(21)00203\u20105"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3655"},{"issue":"1","key":"e_1_2_10_16_1","first-page":"13","article-title":"K\u00f6nnen Routinedaten zur Bestimmung der Zielpopulation in der Indikation Diabetes mellitus Typ 2 in fr\u00fchen Nutzenbewertungen in Deutschland genutzt werden?","volume":"82","author":"Thoren C","year":"2019","journal-title":"Gesundheitswesen"},{"key":"e_1_2_10_17_1","unstructured":"Gemeinsamer Bundesausschuss.\u00c4nderung Der Arzneimittel\u2010Richtlinie (AM\u2010RL): Anlage XII\u2014Nutzenbewertung Von Arzneimitteln Mit Neuen Wirkstoffen Nach \u00a7 35a SGB V Dulaglutid. Bundesanzeiger.2020. Published July 16 2020. Accessed August 23 2021.https:\/\/www.bundesanzeiger.de\/pub\/de\/amtliche-veroeffentlichung?1"},{"key":"e_1_2_10_18_1","unstructured":"Bundesminsterium f\u00fcr Gesundheit.Mitgliederstatistik KM6: Teil I. Published August 20 2018. Accessed August 23 2021.https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM6_2018.xlsx"},{"key":"e_1_2_10_19_1","unstructured":"International Diabetes Federation.IDF Diabetes Atlas.8th ed.2017. Accessed July 22 2021.https:\/\/diabetesatlas.org"},{"issue":"1","key":"e_1_2_10_20_1","first-page":"48","article-title":"12\u2010Monats\u2010Pr\u00e4valenz des bekannten Diabetes mellitus in Deutschland","volume":"2","author":"Heidemann C","year":"2017","journal-title":"J Health Monit"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014796"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07\u20101443"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00138"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.32215"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/20420188211030144"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"issue":"3","key":"e_1_2_10_27_1","first-page":"98","article-title":"Prevalence, incidence and mortality of diabetes mellitus in adults in Germany: a review in the framework of the diabetes surveillance","volume":"2","author":"Heidemann C","year":"2017","journal-title":"J Health Monit"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.14924","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.14924","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.14924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:24:42Z","timestamp":1761891882000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.14924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/dom.14924"],"URL":"https:\/\/doi.org\/10.1111\/dom.14924","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.14924\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.14924\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"2022-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}